



# Epidemiology of Febrile Neutropenic and Bacteremic Patients in the Extensively Drug-Resistant Era

Umran Sumeyse Elbahr <sup>1,\*</sup>, Amira Ahmed <sup>2</sup>, Suha Hejres <sup>3</sup>, Zeki Surmeli <sup>4</sup>, Cigdem Ozturk-Pala <sup>5</sup>, Clark Steven San Diego Delos Reyes <sup>1</sup>, Mohamed Elbahr <sup>6</sup>, Handan Ankaralı <sup>7</sup>, Jordi Rello <sup>8,9</sup>, Hakan Erdem <sup>1</sup>

<sup>1</sup> Department of Infectious Diseases, Bahrain Oncology Center, King Hamad University Hospital, AlMuharraq, Kingdom of Bahrain

<sup>2</sup> Department of Microbiology, King Hamad University Hospital, AlMuharraq, Kingdom of Bahrain

<sup>3</sup> Blood Bank and Laboratory Medicine, Department of Pathology, King Hamad University Hospital, AlMuharraq, Kingdom of Bahrain

<sup>4</sup> Department of Oncology, Bahrain Oncology Center, King Hamad University Hospital, AlMuharraq, Kingdom of Bahrain

<sup>5</sup> Department of Hematology, Bahrain Oncology Center, King Hamad University Hospital, AlMuharraq, Kingdom of Bahrain

<sup>6</sup> Department of Adult Critical Care, King Hamad University Hospital, AlMuharraq, Kingdom of Bahrain

<sup>7</sup> Department of Biostatistics and Medical Informatics, School of Medicine, Istanbul Medeniyet University, Istanbul, Turkey

<sup>8</sup> Clinical Research CHRU, Nîmes, France

<sup>9</sup> Vall d'Hebron Institute of Research, Barcelona, Spain

\* Corresponding author: Department of Infectious Diseases, Bahrain Oncology Center, King Hamad University Hospital, AlMuharraq, Kingdom of Bahrain. Email: drumran\_08@hotmail.com

**Received** 2023 February 6; **Revised** 2023 November 25; **Accepted** 2023 December 3.

## Abstract

**Background:** Appropriate empiric antibiotic use is of utmost importance in febrile neutropenic patients. This study analyzed positive blood culture reports from febrile neutropenic patients and provided a new empirical antibiotic treatment approach.

**Methods:** This study retrospectively enrolled febrile neutropenic patients with hematological or solid organ malignancies who had positive blood cultures at the Bahrain Oncology Center within January 2019 to August 2021. Microbiological data were used to draw inferences for rational antimicrobial treatment. The quick sequential organ failure assessment (qSOFA) score was employed to classify the severity status. The *t*-test was used to compare univariate and multivariate sensitivity values for two dependent proportions.

**Results:** A total of 73 episodes of bacteremia were detected in 53 patients. Among these, 54 episodes (74%) were caused by gram-negative organisms. The most commonly isolated organisms were *Escherichia coli* (30%), *Klebsiella pneumoniae* (22%), and coagulase-negative staphylococci (11%). The rate of extensively drug-resistant strains among *K. pneumoniae* was 44% (*n* = 7). Among gram-negative microorganisms, the susceptibility rates for monotherapies were reported for ceftazidime (56%), piperacillin/tazobactam (76%), cefepime (54%), meropenem (80%), and ceftazidime-avibactam (91%). The susceptibility rates for tigecycline-based combinations exceeded 90% overall.

**Conclusions:** Clinical severity and local epidemiological data should be considered in the management of febrile neutropenia. New antibiotics and tigecycline should be considered for combination therapy in selected cases due to the increasing resistance observed.

**Keywords:** Bacteremia, Empiric Antibiotic, Extensively Drug-Resistant, Febrile Neutropenia, qSOFA

## 1. Background

The development of a series of new chemotherapeutic and biological agents has significantly reduced cancer-related mortality (1). However, these treatments are frequently associated with severe immunosuppression, leading to a higher risk of infection. Neutropenia remains the most

commonly observed adverse outcome of anti-neoplastic chemotherapy, and infections of all types have increased in patients with neutropenia (2). Therefore, appropriate empiric antimicrobial therapy is crucial for patients with febrile neutropenia (FN) and is associated with improved outcomes (3-5). Since there are variations among institutions and geographic areas, specific

antimicrobial treatment regimens should be based on local epidemiologic data (3, 6).

Local epidemiological profiles of infecting microorganisms in hospitals commonly vary. Consequently, providing appropriate antimicrobial regimens for FN patients relies on detecting these local changes in a timely manner (7).

## 2. Objectives

This retrospective study was conducted to document the bacterial spectrum and susceptibility patterns of the pathogens isolated from blood cultures, which are directly suggestive of true pathogens. This will enable us to provide a reliable empirical treatment strategy for hospitalized FN patients in the setting of extensive resistance.

## 3. Methods

Hospitalized FN patients with positive blood cultures at the Bahrain Oncology Center between January 2019 and September 2021 were included in this study. This study retrospectively reviewed the medical records through the electronic hospital information system for all clinical and microbiological data. Blood culture results were collected as the sole microbiological data to eliminate the possibility of colonization as much as possible. The study was approved by the Institutional Review Board of King Hamad University hospital, Al Sayh, Bahrain (22-480).

### 3.1. Inclusion Criteria

Patients with hematological or solid organ malignancies who experienced FN and had positive blood cultures were included.

### 3.2. Exclusion Criteria

Patients under 18 years of age, those with fungemia, or those with contaminated blood cultures were excluded. Contamination was defined as the isolation of usual skin colonizer gram-positive microorganisms from at least one set of two or more blood cultures, along with the absence of clinical findings indicating infection with the isolated microorganism.

Febrile neutropenia was defined as: (1) absolute neutrophil count  $\leq 0.5$  and those expected to be  $\leq 0.5$

within 2 days; (2) a single oral temperature measurement of  $\geq 38.3^{\circ}\text{C}$  ( $101^{\circ}\text{F}$ ) or a temperature of  $\geq 38.0^{\circ}\text{C}$  ( $100.4^{\circ}\text{F}$ ) sustained over 1 hour.

### 3.3. Severity Status of the Patients

The severity status of the patients was classified using the quick sequential organ failure assessment (qSOFA) score (8). Patients were categorized into two groups as follows: Mild patients (qSOFA  $< 2$ ) and critical patients (qSOFA  $\geq 2$ ). Additionally, septic shock was defined as persisting hypotension requiring vasopressors to maintain a mean arterial pressure of 65 mmHg or higher despite adequate volume resuscitation (9).

### 3.4. Microbiological Procedure

Blood cultures were obtained from both central (if in place) and peripheral lines; otherwise, two peripheral samples were collected. Blood cultures were processed using the Bactec blood culture system. Organisms were identified through routine bacteriological procedures. Antibiotic susceptibility testing was performed using the automated Phoenix system (Becton-Dickinson, MD, USA). Results were interpreted according to the Clinical Laboratory Standards Institute guidelines.

The anti-staphylococcal activity of ceftazidime and ceftazidime-avibactam was disregarded, as it has been recommended to exclude testing and reporting of staphylococcal susceptibility to ceftazidime. Therefore, by testing, methicillin was not performed, and staphylococcal strains were considered resistant to these two agents (10, 11).

### 3.5. Statistical Analysis

A *t*-test was used to compare antimicrobial susceptibility values between two dependent proportions.

## 4. Results

A total of 73 bacteremia episodes were included in the survey. In this study, 15 patients with contaminated blood cultures and 6 patients with fungemia were excluded. The participants' mean age was  $61.2 \pm 15.3$  years, and 58% were females. No polymicrobial bacteremia was detected. The most frequent underlying diagnosis was diffuse large B cell lymphoma ( $n = 13$ , 25%),

followed by acute myeloid leukemia (n = 11, 21%) and multiple myeloma (n = 4, 8%). The characteristics of the patients are shown in Table 1.

**Table 1.** Patients' Characteristics

Variables	No. (%)
Age (mean $\pm$ SD)	61.2 $\pm$ 15.3
Gender (female)	31 (58)
<b>Underlying diagnosis</b>	
Solid tumors	16 (30)
Breast cancer	5 (9)
Pancreatic cancer	2 (4)
Bladder cancer	1 (2)
Cervix carcinoma	1 (2)
Cholangiocellular carcinoma	1 (2)
Colon carcinoma	1 (2)
Neuroendocrine tumor	1 (2)
Ovarian cancer	1 (2)
Rectal cancer	1 (2)
Sarcoma	1 (2)
Stomach cancer	1 (2)
Hematologic malignancy	37 (70)
Diffuse large B cell lymphoma	13 (25)
AML	11 (21)
Multiple myeloma	4 (8)
Acute lymphoblastic leukemia	1 (2)
Angioimmunoblastic T-cell lymphoma	1 (2)
Aplastic anemia	1 (2)
Non-Hodgkin's lymphoma	1 (2)
Plasma cell leukemia	1 (2)
Waldenstrom's macroglobulinemia	1 (2)
Chronic myelomonocytic leukemia	1 (2)
Myelodysplastic syndrome	1 (2)
Follicular lymphoma	1 (2)
Total	53

Abbreviation: AML, acute myeloid leukemia.

#### 4.1. Antimicrobial Prophylaxis

Antiviral, antibacterial, or antifungal prophylaxis was ongoing in 31 patients (58.5%). Antibacterial prophylaxis was used by 25 patients (47.1%), including 20 on co-trimoxazole, 18 on levofloxacin, and 1 on cefuroxime axetile. Antifungal prophylaxis was administered to 26 patients (49.0%), with 20 cases receiving fluconazole, 3 cases of posaconazole, 2 cases of voriconazole, and 1 case of liposomal amphotericin B. Antiviral prophylaxis was prescribed for 27 patients (51%), all of whom were taking valacyclovir.

**Comorbid Conditions:** Among the patients, 35 subjects (66%) had comorbidities, including 19 (36%) with hypertension, 13 (24.5%) with diabetes mellitus, 9 (17%) with ischemic heart disease, 7 (13.2%) with hyperlipidemia, 4 (7.5%) with pulmonary emboli, 4 (7.5%) with hypothyroidism, 4 (7.5%) with glucose-6-phosphate dehydrogenase (G6PD) deficiency, 2 (3.7%) with obstructive sleep apnea, 2 (3.7%) with anal fissure, 2 (3.7%) with chronic kidney disease, and 6 (11.3%) with other conditions.

#### 4.2. Infection History

A history of previous infections within the last 3 months was recorded in 19 (35.8%) patients, including 9 (17%) with urinary tract infections (UTIs), 3 (5.6%) with bloodstream infections, 2 (3.7%) with infectious diarrhea, 2 (3.7%) with lower respiratory tract infections, 2 (3.7%) with skin and soft tissue infections, and 1 (1.8%) with an upper respiratory tract infection.

#### 4.3. Microbiological Findings

Among the 73 isolates, 19 (26%) were gram-positive organisms; however, gram-negative organisms accounted for 54 (74%) of the bacteremia episodes. The most frequently isolated microorganisms included *Escherichia coli* in 22 (30%) cases, *Klebsiella pneumoniae* in 16 (22%) cases, and coagulase-negative staphylococci (CoNS) in 8 (11%) cases. Out of 11 *Staphylococcus aureus* isolates, 6 (8%) were methicillin-resistant *Staphylococcus aureus* (MRSA). *Pseudomonas aeruginosa* was found in 5 (7%) of the bloodstream infections.

#### 4.4. Antimicrobial Susceptibility Rate of Monotherapy

Antibiotic susceptibilities of the bacteria isolated from blood cultures were analyzed to assess the effectiveness of empiric antimicrobial therapy. Among gram-negative microorganisms, the susceptibility rates of commonly used monotherapy antibiotics for febrile neutropenia were reported for ceftazidime 30 (56%), piperacillin/tazobactam 41 (76%), cefepime 29 (54%), and meropenem 43 (80%). Ceftazidime-avibactam had the highest susceptibility rate at 91%, followed by colistin at 87%, amikacin at 83%, and tigecycline at 81%. For gram-positive organisms, a 100% susceptibility rate was observed for vancomycin, tigecycline, and linezolid. The

**Table 2.** Antimicrobial Susceptibility Pattern of Gram-Negative Microorganisms <sup>a</sup>

Variables	PIP-TAZO	CAZ	FEP	MEM	AK	CIP	TGC	CT	CAZ-AVI
<i>Escherichia coli</i> (n = 22)	20	13	13	20	22	9	22	22	22
<i>K. pneumoniae</i> (n = 16)	8	3	3	9	9	3	14	12	15
<i>P. aeruginosa</i> (n = 5)	5	5	5	5	5	5	0	5	5
<i>Acinetobacter</i> spp. (n = 4)	3	3	3	3	3	2	3	4	0
<i>Aeromonas</i> spp. (n = 2)	2	2	2	2	2	2	2	2	2
<i>S. maltophilia</i> (n = 1)	0	1	0	0	0	0	1	0	1
<i>E. cloacae</i> (n = 1)	1	1	1	1	1	1	1	1	1
<i>Vibrio</i> spp. (n = 1)	1	1	1	1	1	1	1	1	1
<i>P. mirabilis</i> (n = 1)	1	1	1	1	1	1	0	0	1
<i>R. mucosa</i> (n = 1)	0	0	0	1	1	1	0	0	1
<b>Total (n = 54)</b>	<b>41 (76%)</b>	<b>30 (56%)</b>	<b>29 (54%)</b>	<b>43 (80%)</b>	<b>45 (83%)</b>	<b>21 (46%)</b>	<b>44 (81%)</b>	<b>47 (87%)</b>	<b>49 (91%)</b>

<sup>a</sup> PIP-TAZO, piperacillin-tazobactam; CAZ, ceftazidim; FEP, cefepim; MEM, meropenem; AK, amikacin; CIP, ciprofloxacin; TGC, tigecycline; CT, colistin; CAZ-AVI, ceftazidim-avibactam.

**Table 3.** Antimicrobial Susceptibility Pattern of Gram-Positive Microorganisms <sup>a</sup>

Variables	PIP-TAZ	FEP	MEM	CIP	TGC	VA	LZD
CoNS (n = 8)	2	2	2	3	8	8	8
<i>Staphylococcus aureus</i> (n = 6)	5	5	5	5	6	6	6
<i>Enterococcus faecalis</i> (n = 2)	2	0	2	1	2	1	2
$\alpha$ -hemolytic <i>Streptococcus</i> (n = 1)	1	1	1	1	1	1	1
<i>Corynebacterium simulans</i> (n = 1)	1	1	1	0	1	1	1
<i>Streptococcus gallolyticus</i> (n = 1)	1	1	1	0	1	1	1
<b>Total (n = 19)</b>	<b>12 (63%)</b>	<b>10 (53%)</b>	<b>12 (63%)</b>	<b>10 (53%)</b>	<b>19 (100%)</b>	<b>19 (100%)</b>	<b>19 (100%)</b>

<sup>a</sup> CoNS, coagulase-negative staphylococci; PIP-TAZ, piperacillin-tazobactam; FEP, cefepime; MEM, meropenem; CIP, ciprofloxacin; TGC, tigecycline; VA, vancomycin; LZD, linezolid.

susceptibility patterns of gram-negative and gram-positive microorganisms are summarized in [Tables 2.](#) and [3.](#)

#### 4.5. Antimicrobial Susceptibility Rate of Combination Therapy

The antibiotic combinations were considered efficient with the understanding of the susceptibility of one of the antimicrobials in the combination regimen at the minimum. Tigecycline-based combinations had higher susceptibility rates, with more than 90%. The sensitivity rates of ceftazidime ( $P = 0.033$ ), cefepime ( $P = 0.046$ ), and ciprofloxacin ( $P = 0.018$ ) monotherapies were significantly lower than their combinations with amikacin. The antimicrobial sensitivity rates for combination regimens are shown in [Table 4.](#)

#### 4.6. Resistance Profile

*Klebsiella pneumoniae* had the highest proportion of resistant strains, with 7 (44%) extensively drug-resistant (XDR), 4 (25%) extended-spectrum beta-lactamase (ESBL), and 2 (12.5%) multidrug-resistant (MDR). Among *E. coli* strains, 5 (22.7%) of them produced ESBL, 3 (13.6%) of them had MDR, and no XDR was detected. Methicillin-resistance rate was 70% in staphylococcal strains. Resistance patterns are shown in [Table 5.](#)

### 5. Discussion

The most commonly isolated pathogens were *E. coli*, followed by *K. pneumoniae* among gram-negative microorganisms, and CoNS among gram-positive microorganisms. Similar findings have been reported in the literature (3, 12, 13). Although there were no significant changes in the bacterial spectrum, the increasing antimicrobial resistance patterns will pose challenges for treating clinicians and might necessitate modifications of empirical therapeutic approaches to

**Table 4.** Antibiotic Susceptibility Rates of Certain Antibiotics and Their Combinations for All Isolates

Variables (N = 73)	Susceptibility <sup>a</sup>	Susceptibility in Combination with					
		Quinolones <sup>a</sup>	P-Value	Amikacin <sup>a</sup>	P-Value	Tigecycline <sup>a</sup>	P-Value
Piperacillin-tazobactam	53 (73)	57 (78)	> 0.05	57 (78)	> 0.05	70 (96)	0.05
Meropenem	55 (75)	58 (79)	0.05	57 (78)	> 0.05	71 (97)	0.05
Tigecycline	62 (85)	69 (95)	> 0.05	70 (90)	> 0.05	NA	NA
Amikacin	45 (62)	55 (75)	> 0.05	NA	NA	70 (96)	0.009
Ceftazidime	31 (42)	44 (60)	> 0.05	47 (64)	0.033	68 (93)	0.0011
Cefepime	38 (52)	46 (63)	0.05	54 (74)	0.046	69 (95)	0.0011
Ciprofloxacin	35 (48)	NA	NA	55 (75)	0.018	69 (95)	0.0005
Colistin	47 (64)	59 (80)	> 0.05	50 (68)	> 0.05	70 (96)	0.015
Ceftazidime-avibactam	50 (68)	57 (78)	> 0.05	53 (73)	> 0.05	64 (88)	> 0.05


<sup>a</sup> Values are expressed as No. (%).

prevent poor outcomes. Consequently, antimicrobial resistance could undermine the effectiveness of the antimicrobial therapy recommendations provided by the most recent guidelines. This study demonstrated that the monotherapy regimens endorsed by the current guidelines (3, 14) covered less than one-fourth of FN patients with bacteremia. Therefore, new recommendations that consider the severity of FN patients, in particular, should be provided.

Carbapenem-resistant *Enterobacteriaceae* (CRE) is a recent worldwide concern. The prevalence of colonization by carbapenemase-producing *K. pneumoniae* has progressively increased in recent years (15). Accordingly, carbapenem resistance among gram-negative microorganisms isolated from blood cultures was observed to be associated with high mortality in FN patients (16). In the present study, almost half of *K. pneumoniae* and all *Pseudomonas aeruginosa* strains were resistant to carbapenems. Therefore, these excessively high rates necessitate consideration of carbapenem resistance in empirical FN treatment in such settings. The question arises of how carbapenems alone can be used to treat severe FN patients empirically, especially in the presence of such resistance.

Although current guidelines recommend standard monotherapy for all FN patients, the severity of FN patients should be considered when determining the empirical regimen in highly resistant settings. Various criteria have been suggested for identifying the risk factors of CRE-bloodstream infection (BSI) in immunocompetent patients, including severe sepsis or septic shock at presentation (17). It has also been shown

that the qSOFA score can be a useful bedside tool in predicting the prognosis of FN patients (8, 18). Therefore, this study suggests using the qSOFA score, along with the vasopressor requirement, as a quick evaluation tool for classification (Figure 1).



**Figure 1.** Febrile neutropenia management algorithm by using quick sequential organ failure assessment (qSOFA) score along with vasopressor requirement. AK: Amikacin; Ampho-B: Liposomal amphotericin B; BP: Blood pressure; CAZ-AVI: Ceftazidime avibactam; Cep: Cephalosporin; Cip: Ciprofloxacin; CLABSI: Central line associated blood stream infection; Fq: Fluoroquinolone; IMP: Imipenem; MER: Meropenem; Pen: Penicillin; Pip-tazo: Piperacillin tazobactam; R: Resistant; Tyg: Tigecycline.

An effective antimicrobial stewardship program has been shown to reduce mortality in FN patients, even

**Table 5.** Resistance Patterns

Variables	XDRO, n = 7	MDRO, n = 12	ESBL, n = 9
<i>Klebsiella pneumoniae</i>	7	2	4
<i>Escherichia coli</i>	-	3	5
CoNS <sup>a</sup>	-	6	-
<i>Staphylococcus aureus</i> <sup>a</sup>	-	1	-

Abbreviations: XDRO, extensively drug-resistant organisms; MDRO, multi-drug resistant organisms; ESBL, extended-spectrum beta-lactamase; CoNS, coagulase-negative staphylococci.

<sup>a</sup> All MDRO are methicillin-resistant.

when broad-spectrum antimicrobial regimens are necessary due to the potential for colonization with resistant pathogens (19). In highly resistant settings, part of antimicrobial stewardship involves sparing carbapenems in appropriate patients (20). Given the widespread carbapenem resistance in the studied facility, it seems reasonable to avoid carbapenems in relatively mild infections and consider other monotherapy options. On the other hand, in Bahrain, the available antipseudomonal cephalosporins, ceftazidime, and cefepime have lower efficacy compared to piperacillin-tazobactam. Therefore, piperacillin-tazobactam appears to be a reliable agent for the treatment of mild FN patients.

However, intravenous (IV) combination therapy could be considered when antimicrobial resistance is suspected, especially considering the high resistance profiles of infecting microorganisms in Bahrain. Antibiotic combinations are inevitable in the management of critically ill patients, in particular. According to the present study data, there were significant differences between ceftazidime/cefepime monotherapies and their combinations with tigecycline. Therefore, it would be an appropriate approach to use these antibiotics in combination with tigecycline in critically ill patients who do not require vasopressors. Although the use of tigecycline in bacteremia is controversial, as it is known to be bacteriostatic and has low serum levels (21), it has been reported that combination therapy with tigecycline is more effective than monotherapy in FN patients with BSI (22). The present study revealed that tigecycline-based combinations provide broad coverage and can be used in critical patients.

The empirical use of vancomycin is currently recommended only in certain criteria, including cases

of shock, according to current guidelines (3, 23). However, critical FN patients with sepsis (qSOFA  $\geq 2$ ) are not included in these guidelines when hypotension is absent. Given the 10% rate of methicillin resistance among gram-positive bacteria in the present study and the high mortality rates associated with the inappropriate use of antibiotics in FN patients, it is recommended to use vancomycin empirically in all patients with critical status.

Sepsis is a highly critical condition that requires immediate administration of appropriate antibiotics (24). The use of carbapenems might be inadequate due to the high incidence of CRE in the studied hospital. In CRE patients, empirically recommended antibiotics include ceftazidime-avibactam and ceftolozane-tazobactam due to their efficacy against carbapenemase-producing microorganisms (25). This study has included ceftazidime-avibactam in the flowchart since it is available in the studied facility and has more than 90% efficacy against gram-negative pathogens. However, using ceftazidime-avibactam in combination therapy is more appropriate since it is ineffective against gram-positive bacteria and *Acinetobacter* spp. (10).

This study is limited by its retrospective design. Nevertheless, the study's strength lies in its inclusion of only blood cultures to assess microbiological data, limiting the inclusion of colonizers. In conclusion, the in vitro findings of the present study suggest that clinical severity and local epidemiological data should be considered in FN management rather than applying a uniform approach to all patients. Antibiotics targeting CRE can be considered part of combination therapy in selected cases in settings with high XDR rates. Tigecycline can be considered due to its broad coverage, but only in combination therapy. Given the rate of gram-



positive infection in FN patients, vancomycin should be considered in cases of sepsis (qSOFA  $\geq 2$ ), in addition to glycopeptide indications in the current guidelines. However, further clinical studies are needed to confirm the clinical relevance of these in vitro findings. Finally, the increasing rates of resistance emphasize the need for effective antimicrobial stewardship programs.

## Footnotes

**Authors' Contribution:** Conceptualization: H. E.; methodology: H. E. and U. S. E.; formal analysis: H. A. and J. R.; investigation: A. A. and S. H.; data curation: C. S. D. R.; writing-original draft preparation: U. S. E. and M. E.; writing-review and editing: H. E., Z. G. S., and C. P.; supervision: H. E. All authors have read and agreed to the published version of the manuscript.

**Conflict of Interests:** The authors declare no conflict of interest.

**Data Availability:** The dataset presented in the study is available on request.

**Ethical Approval:** The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board (IRB) of King Hamad University hospital (22-480).

**Funding/Support:** This study received no external funding.

## References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. *CA Cancer J Clin*. 2018;**68**(1):7-30. [PubMed ID: 29313949]. <https://doi.org/10.3322/caac.21442>.
2. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. *Cancer*. 2004;**100**(2):228-37. [PubMed ID: 14716755]. <https://doi.org/10.1002/cncr.11882>.
3. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JJ, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. *Clin Infect Dis*. 2011;**52**(4):e56-93. [PubMed ID: 21258094]. <https://doi.org/10.1093/cid/cir073>.
4. Flowers CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, Hawley DK, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol*. 2013;**31**(6):794-810. [PubMed ID: 23319691]. <https://doi.org/10.1200/JCO.2012.45.8661>.
5. Baden LR, Bensinger W, Angarone M, Casper C, Dubberke ER, Freifeld AG, et al. Prevention and treatment of cancer-related infections. *J Natl Compr Canc Netw*. 2012;**10**(11):1412-45. [PubMed ID: 23138169]. <https://doi.org/10.6004/jnccn.2012.0146>.
6. Montassier E, Batard E, Gastinne T, Potel G, de La Cochetiere MF. Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance. *Eur J Clin Microbiol Infect Dis*. 2013;**32**(7):841-50. [PubMed ID: 23354675]. <https://doi.org/10.1007/s10096-013-1819-7>.
7. Nesher L, Rolston KV. The current spectrum of infection in cancer patients with chemotherapy related neutropenia. *Infection*. 2014;**42**(1):5-13. [PubMed ID: 23975584]. <https://doi.org/10.1007/s15010-013-0525-9>.
8. Lee SJ, Kim JH, Han SB, Paik JH, Durey A. Prognostic Factors Predicting Poor Outcome in Cancer Patients with Febrile Neutropenia in the Emergency Department: Usefulness of qSOFA. *J Oncol*. 2018;**2018**:2183179. [PubMed ID: 30405714]. [PubMed Central ID: PMC6201329]. <https://doi.org/10.1155/2018/2183179>.
9. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA*. 2016;**315**(8):801-10. [PubMed ID: 26903338]. [PubMed Central ID: PMC4968574]. <https://doi.org/10.1001/jama.2016.0287>.
10. European Committee on Antimicrobial Susceptibility Testing. *Breakpoint tables for interpretation of MICs and zone diameters. Version 12.0.* 2022. Available from: [https://eucast.org/clinical\\_breakpoints/](https://eucast.org/clinical_breakpoints/).
11. Dien Bard J, Hindler JA, Gold HS, Limbago B. Rationale for eliminating Staphylococcus breakpoints for beta-lactam agents other than penicillin, oxacillin or cefoxitin, and ceftaroline. *Clin Infect Dis*. 2014;**58**(9):1287-96. [PubMed ID: 24457339]. [PubMed Central ID: PMC5734619]. <https://doi.org/10.1093/cid/ciu043>.
12. Yadegarynia D, Fatemi A, Mahdizadeh M, Kabiri Movahhed R, Alizadeh MA. Current spectrum of bacterial infections in patients with nosocomial fever and neutropenia. *Caspian J Intern Med*. 2013;**4**(3):698-701. [PubMed ID: 24009963]. [PubMed Central ID: PMC375838].
13. Karanwal AB, Parikh BJ, Goswami P, Panchal HP, Parekh BB, Patel KB. Review of clinical profile and bacterial spectrum and sensitivity patterns of pathogens in febrile neutropenic patients in hematological malignancies: A retrospective analysis from a single center. *Indian J Med Paediatr Oncol*. 2013;**34**(2):85-8. [PubMed ID: 24049293]. [PubMed Central ID: PMC3764750]. <https://doi.org/10.4103/0971-5851.116184>.
14. Averbuch D, Orasch C, Cordonnier C, Livermore DM, Mikulska M, Viscoli C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. *Haematologica*. 2013;**98**(12):1826-35. [PubMed ID: 24323983]. [PubMed Central ID: PMC3856957]. <https://doi.org/10.3324/haematol.2013.091025>.
15. Micozzi A, Gentile G, Santilli S, Minotti C, Capria S, Moleti ML, et al. Reduced mortality from KPC-K.pneumoniae bloodstream infection in high-risk patients with hematological malignancies colonized by KPC-K.pneumoniae. *BMC Infect Dis*. 2021;**21**(1):1079. <https://doi.org/10.1186/s12879-021-06747-8>.

16. Kara Ali R, Surme S, Balkan II, Salihoglu A, Sahin Ozdemir M, Ozdemir Y, et al. An eleven-year cohort of bloodstream infections in 552 febrile neutropenic patients: resistance profiles of Gram-negative bacteria as a predictor of mortality. *Ann Hematol.* 2020;**99**(8):1925-32. [PubMed ID: 32564194]. <https://doi.org/10.1007/s00277-020-04144-w>.
17. Cano A, Gutierrez-Gutierrez B, Machuca I, Gracia-Ahufinger I, Perez-Nadales E, Causse M, et al. Risks of Infection and Mortality Among Patients Colonized With *Klebsiella pneumoniae* Carbapenemase-Producing *K. pneumoniae*: Validation of Scores and Proposal for Management. *Clin Infect Dis.* 2018;**66**(8):1204-10. [PubMed ID: 29126110]. <https://doi.org/10.1093/cid/cix991>.
18. İpekci A, Kanbakan A, Akdeniz YS, Çakmak F, Biberoglu S, Özkan S, et al. Scoring Systems Identifying the Low-Risk Febrile Neutropenia Patients in the Emergency Department: Usefulness of MASCC, CISNE and qSOFA. *Phoenix Med J.* 2021;**3**(3):118-22. <https://doi.org/10.38175/phnx.992230>.
19. Rosa RG, Goldani LZ, dos Santos RP. Association between adherence to an antimicrobial stewardship program and mortality among hospitalised cancer patients with febrile neutropaenia: a prospective cohort study. *BMC Infect Dis.* 2014;**14**:286. [PubMed ID: 24884397]. [PubMed Central ID: PMC4039648]. <https://doi.org/10.1186/1471-2334-14-286>.
20. Metan G, Kaynar L, Yozgat N, Elmali F, Kurkcuoglu CA, Alp E, et al. A change for the antibacterial treatment policy to decrease carbapenem consumption at a haematopoietic stem cell transplantation centre. *Infez Med.* 2017;**25**(1):33-7. [PubMed ID: 28353453].
21. Stein GE, Babinchak T. Tigecycline: an update. *Diagn Microbiol Infect Dis.* 2013;**75**(4):331-6. [PubMed ID: 23357291]. <https://doi.org/10.1016/j.diagmicrobio.2012.12.004>.
22. Bucaneve G, Micozzi A, Picardi M, Ballanti S, Cascavilla N, Salutari P, et al. Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia. *J Clin Oncol.* 2014;**32**(14):1463-71. [PubMed ID: 24733807]. <https://doi.org/10.1200/JCO.2013.51.6963>.
23. No Authors Listed. 2019 surveillance of neutropenic sepsis: prevention and management in people with cancer (NICE guideline CG151) [Internet]. London: National Institute for Health and Care Excellence; 2019.
24. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. *Crit Care Med.* 2021;**49**(11):e1063-143. <https://doi.org/10.1097/ccm.0000000000005337>.
25. Tatarelli P, Mikulska M. Multidrug-resistant bacteria in hematology patients: emerging threats. *Future Microbiol.* 2016;**11**:767-80. [PubMed ID: 27196948]. <https://doi.org/10.2217/fmb-2015-0014>.